MEIP Share Price

Open 2.28 Change Price %
High 2.38 1 Day 0.02 0.87
Low 2.26 1 Week -0.09 -3.73
Close 2.32 1 Month -0.43 -15.64
Volume 202391 1 Year 0.71 44.10
52 Week High 3.26
52 Week Low 1.34
MEIP Important Levels
Resistance 2 2.43
Resistance 1 2.39
Pivot 2.32
Support 1 2.25
Support 2 2.21
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
RCON 2.13 108.82%
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
RITT 0.05 25.00%
LBIX 2.82 24.23%
CNET 1.34 19.64%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

MEI Pharma, Inc. (NASDAQ: MEIP)

MEIP Technical Analysis 2
As on 16th Oct 2017 MEIP Share Price closed @ 2.32 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.01 & Strong Sell for SHORT-TERM with Stoploss of 2.67 we also expect STOCK to react on Following IMPORTANT LEVELS.
MEIP Target for October
1st Target up-side 2.99
2nd Target up-side 3.21
3rd Target up-side 3.43
1st Target down-side 2.37
2nd Target down-side 2.15
3rd Target down-side 1.93
MEIP Other Details
Segment EQ
Market Capital 24491034.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.meipharma.com
MEIP Address
MEIP
11975 El Camino Real
Suite 101
San Diego, CA 92130
United States
Phone: 858-792-6300
MEIP Latest News
Interactive Technical Analysis Chart MEI Pharma, Inc. ( MEIP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on MEI Pharma, Inc.
MEIP Business Profile
MEI Pharma, Inc., formerly Marshall Edwards, Inc., is a development-stage oncology company. The Company is engaged in the development of drugs for the treatment of cancer. The Company focuses on the clinical development of therapeutics targeting cancer metabolism. The Company is a wholly owned subsidiary of Novogen Limited (Novogen). As of September 26, 2011, Novogen owned approximately 51.5% interests in the Company. The Company's has two geographic segments: the United States and Australia. The Company has two clinical product development programs, which include NADH Oxidase Inhibitors and Mitochondrial Inhibitors. NADH Oxidase Inhibitors includes Phenoxodiol and ME-143. Mitochondrial Inhibitors includes NV-128 and ME-344. Marshall Edwards Pty Ltd. is a wholly owned subsidiary of the Company. In February 2013, Novogen Limited completed its exchanged offer through which it was to split off its 63.5% interest in the Company.